Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: An unresolved issue

Lancet Oncology

Volumn 3, Issue 6, 2002, Pages 333-340

  Vento, Sandro ^a,b   Cainelli, Francesca ^a   Longhi, Maria Serena ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; BETA INTERFERON; BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DEOXYGUANOSINE DERIVATIVE; DRUG; EMTRICITABINE; ENTECAVIR; GLUCOCORTICOID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LAMIVUDINE; METHOTREXATE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STEROID; UNINDEXED DRUG; VIRUS DNA; VIRUS RNA;

ANTIVIRAL ACTIVITY; BLOOD DISEASE; CHRONICITY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG WITHDRAWAL; FREQUENCY ANALYSIS; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROLOGY; SOLID TUMOR; SYMPTOMATOLOGY; VIRUS CARRIER; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 0036077794     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(02)00773-8     Document Type: Review

References (60)

1. Hepatotoxicity of chemotherapeutic agents
2. The clinical toxicity of anticancer drugs and its prediction
3. Massive hepatic necrosis after cyclophosphamide
4. Hepatitis C virus infection in patients undergoing marrow transplantation
5. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C
6. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers
7. Fulminant hepatitis due to Epstein-Barr virus infection
8. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
9. Bone-marrow transplantation (II)
10. Chronic graft-versus-host disease syndrome in man: A long-term clinicopathologic study of 20 Seattle patients
11. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
12. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders
13. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy
14. Subacute and chronic active hepatitis after withdrawal of chemotherapy
15. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients
16. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991
17. Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan
18. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy: A prospective study in 305 patients
19. Primary hepatocellular carcinoma with hepatitis B antigenemia: Effects of chemotherapy
20. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
21. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B
22. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors
23. Reactivation of hepatitis B after transplantation operations
24. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation
25. Redevelopment of hepatitis B surface antigen after renal transplantation
26. Recurrence of hepatitis B after single lung transplantation
27. Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemia chemotherapy
28. Hepatitis B: Evolving epidemiology and implications for control
29. Treatment of HBV reactivation after withdrawal of immunosuppression
30. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy
31. A short course of prednisolone in chronic type B hepatitis
32. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg
33. Hepatitis B core antigen (HBcAg) accumulation in an HBV nonproducer clone of HepG2 transfected cells is associated with cytopathic effect
34. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone-marrow transplantation
35. Hepatitis B reactivation following allogeneic bone marrow transplantation: Case report and review of the literature
36. Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: A survey from the European Bone Marrow Transplantation (EBMT) Group-Infectious Diseases Working Party
37. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation
38. Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation
39. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors
40. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study
41. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma
42. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis
43. Hepatitis B virus DNA contains a glucocorticoid-responsive element
44. Steroid free chemotherapy decreases the risk of hepatitis flare ups in hepatitis B virus carriers with non Hodgkin's lymphoma
45. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen
46. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis
47. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
48. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders
49. Non-Hodgkin's lymphoma and hepatitis C virus infection
50. Hepatitis C virus infection and lymphoproliferative diseases: Prospective study on 1,576 patients in France
51. HCV and HGV and non-Hodgkin's lymphoma
52. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
53. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies
54. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C
55. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
56. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B infection
57. L-dt: An ongoing phase I/IIa dose-escalation trial in patients with chronic HBV infection (NV-02-001)
58. Interferon and cyclosporin A in the treatment of fulminant viral hepatitis
59. Liver transplantation for fulminant hepatitis following chemotherapy for malignant lymphoma
60. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy